FDA clears trial testing Mesoblast cell therapy in kids with DMD
WHY IT MATTERS
This trial represents a new treatment approach for DMD in young children who are still in a critical window for muscle development, offering families a potential alternative or complement to existing therapies.
The FDA has approved a clinical trial for a new cell therapy called remestemcel-L-rknd made by Mesoblast. The therapy will be tested in children ages 5-9 who have Duchenne muscular dystrophy (DMD), a serious muscle disease. About 76 children will participate in the trial and receive either the therapy or a placebo while continuing their regular DMD treatments.
The U.S. Food and Drug Administration (FDA) has given Mesoblast the go-ahead to launch a clinical trial testing its cell therapy remestemcel-L-rknd in children with Duchenne muscular dystrophy (DMD). The trial aims to enroll 76 kids with DMD ages 5-9 who are receiving standard-of-care therapies. Participants will be randomly assigned to receive infusions of the […] The post FDA clears trial testing Mesoblast cell therapy in kids with DMD appeared first on Muscular Dystrophy News .
YOU CAN ACT ON THIS
If your child has DMD and is ages 5-9, ask your neurologist or DMD specialist whether your child might be eligible for this trial and how to inquire about enrollment.